GlobeNewswire: Global Blood Therapeutics, Inc. Contains the last 10 of 303 releaseshttp://www.globenewswire.com/External?Length=42024-03-28T13:35:24ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2022/09/15/2517333/0/en/GBT-Supports-the-Sickle-Cell-Disease-Treatment-Centers-Act-of-2022.html?f=22&fvtc=4&fvtv=27009GBT Supports the Sickle Cell Disease Treatment Centers Act of 20222022-09-15T22:00:00Z<![CDATA[Congress Moves to Expand Funding for National Network of Specialized Treatment Centers and Community Organizations for Sickle Cell Disease Patients Congress Moves to Expand Funding for National Network of Specialized Treatment Centers and Community Organizations for Sickle Cell Disease Patients]]>https://www.globenewswire.com/news-release/2022/09/08/2512447/0/en/GBT-and-Sickle-Cell-Disease-Association-of-America-to-Host-11th-Annual-Sickle-Cell-Disease-Therapeutics-Conference.html?f=22&fvtc=4&fvtv=27009GBT and Sickle Cell Disease Association of America to Host 11th Annual Sickle Cell Disease Therapeutics Conference2022-09-08T12:00:00Z<![CDATA[Keynote by Admiral Rachel Levine, M.D., Assistant Secretary for Health, U.S. Department of Health and Human Services Keynote by Admiral Rachel Levine, M.D., Assistant Secretary for Health, U.S. Department of Health and Human Services]]>https://www.globenewswire.com/news-release/2022/08/08/2493680/0/en/Pfizer-to-Acquire-Global-Blood-Therapeutics-for-5-4-Billion-to-Enhance-Presence-in-Rare-Hematology.html?f=22&fvtc=4&fvtv=27009Pfizer to Acquire Global Blood Therapeutics for $5.4 Billion to Enhance Presence in Rare Hematology2022-08-08T10:45:00Z<![CDATA[Proposed acquisition drives growth by bringing leading sickle cell disease expertise, portfolio and pipeline to Pfizer with potential combined worldwide peak sales of more than $3 billion]]>https://www.globenewswire.com/news-release/2022/08/04/2492808/0/en/GBT-Announces-New-Employment-Inducement-Grants.html?f=22&fvtc=4&fvtv=27009GBT Announces New Employment Inducement Grants2022-08-04T20:05:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on August 1, 2022, the compensation committee of GBT’s board of directors granted 10 new employees restricted stock units for an aggregate of 30,450 shares of the company’s common stock. These awards were made under GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan).]]>https://www.globenewswire.com/news-release/2022/08/03/2491766/0/en/GBT-Announces-Participation-at-the-Wedbush-PacGrow-Healthcare-Conference.html?f=22&fvtc=4&fvtv=27009GBT Announces Participation at the Wedbush PacGrow Healthcare Conference2022-08-03T20:05:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., Aug. 03, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will participate in a virtual fireside chat at the Wedbush PacGrow Healthcare Conference on Wednesday, August 10, 2022, at 2:20 p.m. E.T.]]>https://www.globenewswire.com/news-release/2022/07/29/2488710/0/en/GBT-to-Announce-Second-Quarter-2022-Financial-Results-on-Monday-August-8-2022.html?f=22&fvtc=4&fvtv=27009GBT to Announce Second Quarter 2022 Financial Results on Monday, August 8, 20222022-07-29T12:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., July 29, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will report second quarter 2022 financial results on Monday, August 8, 2022, after U.S. financial markets close.]]>https://www.globenewswire.com/news-release/2022/07/26/2485565/0/en/MHRA-Grants-Marketing-Authorization-for-GBT-s-Oxbryta-voxelotor-for-Use-in-Great-Britain-for-the-Treatment-of-Hemolytic-Anemia-in-Patients-with-Sickle-Cell-Disease-Age-12-Years-and.html?f=22&fvtc=4&fvtv=27009MHRA Grants Marketing Authorization for GBT’s Oxbryta® (voxelotor) for Use in Great Britain for the Treatment of Hemolytic Anemia in Patients with Sickle Cell Disease Age 12 Years and Older2022-07-26T07:01:00Z<![CDATA[Voxelotor is the first medicine approved in Great Britain to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell disease Voxelotor is the first medicine approved in Great Britain to directly inhibit sickle hemoglobin (HbS) polymerization, the underlying molecular cause of sickle cell disease]]>https://www.globenewswire.com/news-release/2022/07/14/2479652/0/en/GBT-Initiates-Expanded-Access-Program-for-Voxelotor-in-Patients-With-Sickle-Cell-Disease-in-Brazil.html?f=22&fvtc=4&fvtv=27009GBT Initiates Expanded Access Program for Voxelotor in Patients With Sickle Cell Disease in Brazil2022-07-14T12:00:00Z<![CDATA[SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced the initiation of an expanded access program (EAP) for voxelotor in Brazil for the treatment of sickle cell disease (SCD) in adult and pediatric patients 12 years of age and older who cannot satisfactorily be treated with a medicine authorized for use in Brazil. ANVISA, the Brazilian Health Regulatory Agency, has authorized the voxelotor EAP, which is actively enrolling at clinical sites around the country.]]>https://www.globenewswire.com/news-release/2022/07/14/2479652/0/pt/GBT-Inicia-Programa-de-Acesso-Expandido-para-Voxelotor-em-Pacientes-com-Doen%C3%A7a-Falciforme-no-Brasil.html?f=22&fvtc=4&fvtv=27009 GBT Inicia Programa de Acesso Expandido para Voxelotor em Pacientes com Doença Falciforme no Brasil2022-07-14T12:00:00Z<![CDATA[SÃO PAULO, July 14, 2022 (GLOBE NEWSWIRE) -- A Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) anunciou hoje o início do programa de acesso expandido (PAE) para o voxelotor no Brasil destinado ao tratamento de doença falciforme (DF) em adultos e pacientes pediátricos de 12 anos ou mais que não podem ser tratados de forma satisfatória com um medicamento autorizado para uso no país. A Agência Nacional de Vigilância Sanitária (Anvisa) deu o aval ao programa, que está recrutando pacientes em centros clínicos brasileiros.]]>https://www.globenewswire.com/news-release/2022/07/13/2478946/0/en/The-GBT-Foundation-Awards-250-000-in-ACE-Grants-to-Support-Sickle-Cell-Disease-Community-Based-Organizations.html?f=22&fvtc=4&fvtv=27009The GBT Foundation Awards $250,000 in ACE Grants to Support Sickle Cell Disease Community-Based Organizations2022-07-13T12:00:10Z<![CDATA[SOUTH SAN FRANCISCO, Calif., July 13, 2022 (GLOBE NEWSWIRE) -- The GBT Foundation, a 501(c)(3) organization primarily funded by Global Blood Therapeutics, Inc. (GBT), has awarded grants of approximately $50,000 each to five community-based organizations (CBOs) as recipients of the inaugural Access to Care Empowerment for Sickle Cell (ACE) Grant Program. Through the ACE Grant Program, The GBT Foundation plans to fund up to $250,000 per year to support initiatives dedicated to advancing health equity and enhancing education, empowerment, and access to care for people living with sickle cell disease (SCD).]]>